Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Payables (2023 - 2025)

Historic Payables for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $12.3 million.

  • Tonix Pharmaceuticals Holding's Payables rose 5129.43% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year increase of 5129.43%. This contributed to the annual value of $10.7 million for FY2024, which is 1454.09% down from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Payables stood at $12.3 million for Q3 2025, which was up 5129.43% from $11.1 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Payables' 5-year high stood at $12.5 million during Q4 2023, with a 5-year trough of $7.7 million in Q1 2025.
  • Moreover, its 3-year median value for Payables was $10.4 million (2024), whereas its average is $10.1 million.
  • Over the last 5 years, Tonix Pharmaceuticals Holding's Payables had its largest YoY gain of 5129.43% in 2025, and its largest YoY loss of 2809.09% in 2025.
  • Tonix Pharmaceuticals Holding's Payables (Quarter) stood at $12.5 million in 2023, then dropped by 14.54% to $10.7 million in 2024, then rose by 15.61% to $12.3 million in 2025.
  • Its Payables stands at $12.3 million for Q3 2025, versus $11.1 million for Q2 2025 and $7.7 million for Q1 2025.